Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Subjects:

Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. by Rahsan Erdem (11726357)

Subjects:

Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Scatterplot of iOWH032 plasma concentrations versus diarrheal stool output rate. by Rahsan Erdem (11726357)

Subjects:

Dose- and time-dependent effect of IL-13, IL-4, and TGF-β1 on benzamil-sensitive <i>I</i>_sc and TEER in HBECs. by Anusree Sasidharan (19226521)

Simultaneously inhibition <i>Nlu-miR-34</i> and <i>NlInR2</i> in SW strain induced the decrease of SW BPHs. by Xinhai Ye (6857771)

“…<p>(A) Antagomir-34 (with two different quantities) and ds<i>NlInR2</i> (0.84 ng) were injected into the third instar SW strain nymphs, showed that injection of antagomir-34 decreased the ratio of SW type BPH (Chi-square test, 40ng: χ² = 5.8, df = 1, <i>p</i> = 0.003; 60ng: χ² = 7.9, df = 1, <i>p</i> = 0.042). …”

Flowchart of study selection. by Alejandro Piscoya (782326)

Description of characteristics of included studies. by Alejandro Piscoya (782326)

Effect of remdesivir on invasive ventilation at 14 days. by Alejandro Piscoya (782326)

Effect of remdesivir on all-cause mortality at 14 days. by Alejandro Piscoya (782326)

Summary of findings table for the comparison remdesivir 5 days vs. standard of care for hospitalized, moderate COVID-19. by Alejandro Piscoya (782326)

PK profiles of paeoniflorin and paeonol comparing low and high repeated doses of MC in DNBS-induced colitis rats. by Jin-Hwa Kim (101817)

Subjects: